WAYNE, Pa., Nov. 11 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced the recent appointment of Wall Street veteran Shahab Fatheazam to its Board of Directors.
Shahab Fatheazam, age 58, is currently a Managing Director and head of the U.S. healthcare practice of GCA Savvian, a leading international investment banking advisory firm. Mr. Fatheazam joined GCA Savvian in 2004 from Vector Securities, a premier healthcare specialty firm, where he was a partner. Prior to helping to form Vector Securities, he was co-head of Paine Webber's Lifescience Division. He began his career on Wall Street with Kidder, Peabody & Co, where, in 1980, he became a partner and senior executive in Kidder's international corporate finance unit. Mr. Fatheazam holds a BA and MA from Cambridge University in England and an MBA from Columbia University. Mr. Fatheazam sits on the boards of two biotechnology companies and is a Trustee at Chicago University's Harris School. He is a member of the Economics Club in Chicago.
"We are very pleased to welcome Shahab to our Board," commented Dr. David Ginsberg, President and Chief Executive Officer of Encorium. "With over 30 years of experience in capital markets, mergers and acquisitions and other advisory activities for a broad array of clients in the healthcare industry we believe his advice and counsel will be invaluable as we navigate through the challenges and opportunities ahead."
The appointment of Mr. Fatheazam will return the Board to its prior
size of five directors, before the September
'/>"/>
| SOURCE Encorium Group, Inc. Copyright©2008 PR Newswire. All rights reserved |